Meeting of the Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention, 71276-71277 [2024-19623]
Download as PDF
<![CDATA[
71276
Federal Register / Vol. 89, No. 170 / Tuesday, September 3, 2024 / Notices
individual and compounded barriers on
health outcomes along the CCC for
survivors. CDC will use a mixed
methods data collection and analysis
approach. First, CDC will pull our
sample from cancer registry data in
California, North Carolina, and Texas
based on inclusion criteria (received
first cancer diagnosis of either breast,
cervical or colorectal cancer in 2021;
21–75 years of age at time of diagnosis;
are non-Hispanic Black/African
American, non-Hispanic White, or
Hispanic; alive at the time of data
extraction/sample selection). Then, CDC
will administer a Wave 1 (baseline) and
Wave 2 (one-year follow-up) survey to
cancer survivors, as well as a survey to
their caregivers. Additionally, CDC will
conduct interviews with selected
survivors and caregivers as well as focus
groups with representatives from
patient/survivor advocacy
organizations.
CDC will incorporate cancer registry
data into the quantitative data analysis,
and triangulate findings from the
quantitative and qualitative data
collection efforts. Results will be used to
inform efforts aimed at increasing access
to cancer care services, reducing the
burden of cancers and closing the
disparities gap. CDC requests OMB
approval for an estimated 1,681 annual
burden hours. There are no costs to
respondents other than their time to
participate.
ESTIMATED ANNUALIZED BURDEN HOURS
Form name
Wave 1 Survivor Survey Respondents ...........
Wave 2 Survivor Survey Respondents ...........
Survivor Interviewees ......................................
Caregiver Survey Respondents ......................
Caregiver Interviewees ...................................
Patient Advocacy Group—Focus Group Participants.
W1 Survey Instrument ...................................
W2 Survey Instrument ...................................
Survivor Interview Guide ................................
Caregiver Survey Instrument .........................
Caregiver Interview Guide .............................
Advocacy Representatives Focus Group
Guide.
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–19611 Filed 8–30–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2024–0063]
Meeting of the Advisory Committee to
the Director (ACD), Centers for Disease
Control and Prevention
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
Notice of meeting and request
for comment.
ACTION:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting for the Advisory
Committee to the Director, Centers for
Disease Control and Prevention (ACD,
CDC). This is a hybrid meeting,
accessible both in person and virtually
(webcast live via the World Wide Web).
It is open to the public and limited only
by the space available.
tkelley on LAP7H3WLY3PROD with NOTICES2
SUMMARY:
VerDate Sep<11>2014
22:46 Aug 30, 2024
Jkt 262001
The meeting will be held on
October 22, 2024, from 9 a.m. to 3:30
p.m., EDT (times subject to change).
The public may submit written
comments from September 3, 2024
through October 7, 2024.
ADDRESSES: Meeting address: CDC
Roybal Campus, Building 19,
Auditorium B3, 1600 Clifton Road NE,
Atlanta, Georgia 30329–4027.
Please note that the meeting location,
the CDC Roybal Campus, is a federal
facility and in-person access is limited
to United States citizens unless prior
authorizations, taking up to 30 to 60
days, have been made.
Registration: You must register to
attend this meeting in person. If you
wish to attend in person, please submit
a request by email to ACDirector@
cdc.gov at least 5 business days in
advance of the meeting. No registration
is required to view the meeting via the
World Wide Web. Information for
accessing the webcast will be available
at https://www.cdc.gov/about/advisorycommittee-director/.
Written comments: You may submit
comments, identified by Docket No.
CDC–2024–0063 by either of the
following methods below. Do not
submit comments for the docket by
email. CDC does not accept comments
for the docket by email.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Demetria Gardner, BA,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE,
DATES:
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
Number of
respondents
Type of respondents
3,000
1,200
20
900
20
16
1
1
1
1
1
1
Average
burden per
response
(in hours)
20/60
20/60
1
15/60
1
1
Mailstop H21–10, Atlanta, Georgia
30329–4027. Attn: Docket number CDC–
2024–0063.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
https://www.regulations.gov, suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov. Written
public comments submitted up to 72
hours prior to the ACD meeting will be
provided to ACD members before the
meeting. Written comments received in
advance of the meeting will be included
in the official record of the meeting.
FOR FURTHER INFORMATION CONTACT:
Demetria Gardner, BA, Office of the
Chief of Staff, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE, Mailstop H21–10, Atlanta,
Georgia 30329–4027, Telephone: (770)
488–4745; Email Address: ACDirector@
cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee to
the Director, CDC, shall (1) make
recommendations to the Director
regarding ways to prioritize the
activities of the agency in alignment
with the CDC Strategic Plan required
under section 305(c); H.R. 2617–1252;
(2) advise on ways to achieve or
improve performance metrics in relation
to the CDC Strategic Plan, and other
relevant metrics, as appropriate; (3)
U:\REGISTER\03SEN1.SGM
03SEN1
Federal Register / Vol. 89, No. 170 / Tuesday, September 3, 2024 / Notices
tkelley on LAP7H3WLY3PROD with NOTICES2
provide advice and recommendations
on the development of the Strategic
Plan, and any subsequent updates, as
appropriate; (4) advise on grant,
cooperative agreements, contracts, or
other transactions, as applicable; (5)
provide other advice to the Director, as
requested, to fulfill duties under
sections 301 and 311; and (6) appoint
subcommittees. The committee
recommends ways to prioritize CDC’s
activities, improve results, and address
health disparities. It also provides
guidance to help CDC work more
effectively with its various private and
public sector constituents to make
health protection a practical reality.
Matters to be Considered: The agenda
will include an update on priorities
from the CDC Director, discussions on
strategic science and impact, artificial
intelligence, childhood immunization
coverage and efforts to address lagging
rates, global update, and updates from
the ACD Data and Surveillance
Workgroup and the Communications
and Public Engagement Workgroup.
Agenda items are subject to change as
priorities dictate.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments on September 3, 2024
through October 7, 2024.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
VerDate Sep<11>2014
22:46 Aug 30, 2024
Jkt 262001
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–19623 Filed 8–30–24; 8:45 am]
BILLING CODE 4163–18–P
71277
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2024–0064; NIOSH 248–
L]
Meeting of the World Trade Center
Health Program Scientific/Technical
Advisory Committee
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Advisory Board on Radiation and
Worker Health, Subcommittee for
Procedure Reviews; Cancellation of
Meeting
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
This is to notify the public
that the July 30, 2024, meeting of the
Advisory Board on Radiation and
Worker Health, Subcommittee for
Procedure Reviews is cancelled.
FOR FURTHER INFORMATION CONTACT:
Rashaun Roberts, Ph.D., National
Institute for Occupational Safety and
Health, CDC, 1090 Tusculum Avenue,
Mailstop C–24, Cincinnati, Ohio 45226,
Telephone: (513) 533–6800, Toll Free
1(800) CDC–INFO, Email: ocas@cdc.gov.
SUPPLEMENTARY INFORMATION: Notice is
hereby given of a change in the meeting
of the Advisory Board on Radiation and
Worker Health, Subcommittee for
Procedure Reviews (ABRWH, SPR). The
meeting was announced in the Federal
Register on May 17, 2024, Volume 89,
Number 97, page 43404. This meeting is
being canceled in its entirety. The
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention, has been delegated the
authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
SUMMARY:
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2024–19622 Filed 8–30–24; 8:45 am]
BILLING CODE 4163–18–P
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting for the World Trade
Center Health Program Scientific/
Technical Advisory Committee (STAC).
This virtual meeting is open to the
public. Time will be available for public
comment.
DATES: The meeting will be held on
September 23, 2024, from 11 a.m. to 3
p.m., EDT.
Written public comments must be
received by September 23, 2024, at
11:59 p.m., EDT. Members of the public
who wish to address the STAC during
the oral public comment session must
sign up to speak by September 16, 2024,
at the email address provided in the
Procedure for Oral Public Comment
section below.
ADDRESSES: This is a virtual meeting
conducted via Zoom. The public is
welcome to follow the proceedings via
YouTube Live at the following link:
https://youtube.com/live/7Pokfh4kcsc?
feature=share. No registration is
required. For additional information,
please visit the World Trade Center
Health Program website at https://
www.cdc.gov/wtc/stac_meeting.html.
You may submit comments, identified
by Docket No. CDC–2024–0064; NIOSH
248–L by either of the methods listed
below. CDC does not accept comments
by email.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Ms. Sherri Diana, NIOSH
Docket Office, National Institute for
Occupational Safety and Health, Centers
for Disease Control and Prevention,
1090 Tusculum Avenue, Mailstop C–34,
Cincinnati, Ohio 45226. Attn: Docket
No. CDC–2024–0064; NIOSH 248–L.
Instructions: All submissions received
must include the Agency name and
docket number (CDC–2024–0064;
NIOSH 248–L). The docket will close on
SUMMARY:
U:\REGISTER\03SEN1.SGM
03SEN1
]]>Agencies
[Federal Register Volume 89, Number 170 (Tuesday, September 3, 2024)]
[Notices]
[Pages 71276-71277]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-19623]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2024-0063]
Meeting of the Advisory Committee to the Director (ACD), Centers
for Disease Control and Prevention
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting for the Advisory Committee to the Director, Centers
for Disease Control and Prevention (ACD, CDC). This is a hybrid
meeting, accessible both in person and virtually (webcast live via the
World Wide Web). It is open to the public and limited only by the space
available.
DATES: The meeting will be held on October 22, 2024, from 9 a.m. to
3:30 p.m., EDT (times subject to change).
The public may submit written comments from September 3, 2024
through October 7, 2024.
ADDRESSES: Meeting address: CDC Roybal Campus, Building 19, Auditorium
B3, 1600 Clifton Road NE, Atlanta, Georgia 30329-4027.
Please note that the meeting location, the CDC Roybal Campus, is a
federal facility and in-person access is limited to United States
citizens unless prior authorizations, taking up to 30 to 60 days, have
been made.
Registration: You must register to attend this meeting in person.
If you wish to attend in person, please submit a request by email to
[email protected] at least 5 business days in advance of the meeting.
No registration is required to view the meeting via the World Wide Web.
Information for accessing the webcast will be available at https://www.cdc.gov/about/advisory-committee-director/.
Written comments: You may submit comments, identified by Docket No.
CDC-2024-0063 by either of the following methods below. Do not submit
comments for the docket by email. CDC does not accept comments for the
docket by email.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Demetria Gardner, BA, Centers for Disease Control
and Prevention, 1600 Clifton Road NE, Mailstop H21-10, Atlanta, Georgia
30329-4027. Attn: Docket number CDC-2024-0063.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov, suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
Written public comments submitted up to 72 hours prior to the ACD
meeting will be provided to ACD members before the meeting. Written
comments received in advance of the meeting will be included in the
official record of the meeting.
FOR FURTHER INFORMATION CONTACT: Demetria Gardner, BA, Office of the
Chief of Staff, Centers for Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H21-10, Atlanta, Georgia 30329-4027,
Telephone: (770) 488-4745; Email Address: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee to the Director, CDC, shall (1)
make recommendations to the Director regarding ways to prioritize the
activities of the agency in alignment with the CDC Strategic Plan
required under section 305(c); H.R. 2617-1252; (2) advise on ways to
achieve or improve performance metrics in relation to the CDC Strategic
Plan, and other relevant metrics, as appropriate; (3)
[[Page 71277]]
provide advice and recommendations on the development of the Strategic
Plan, and any subsequent updates, as appropriate; (4) advise on grant,
cooperative agreements, contracts, or other transactions, as
applicable; (5) provide other advice to the Director, as requested, to
fulfill duties under sections 301 and 311; and (6) appoint
subcommittees. The committee recommends ways to prioritize CDC's
activities, improve results, and address health disparities. It also
provides guidance to help CDC work more effectively with its various
private and public sector constituents to make health protection a
practical reality.
Matters to be Considered: The agenda will include an update on
priorities from the CDC Director, discussions on strategic science and
impact, artificial intelligence, childhood immunization coverage and
efforts to address lagging rates, global update, and updates from the
ACD Data and Surveillance Workgroup and the Communications and Public
Engagement Workgroup. Agenda items are subject to change as priorities
dictate.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: The docket will be opened to receive
written comments on September 3, 2024 through October 7, 2024.
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2024-19623 Filed 8-30-24; 8:45 am]
BILLING CODE 4163-18-P
